FDA could fast-track drugs already approved abroad under new bill
In committeeH.R. 7953Latest action
Sponsor: Pete Sessions · Representative · TX
AIDecoded by AI · checked against the recordRead the official text
Official title: FAIR ACT
119th Congress
Topics: Health care
Introduced:
Read the official bill on Congress.govIn plain words
The plain-language version comes first. The official text is always the reference.
The FAIR Act would let the FDA approve life-threatening disease drugs within 30 days if already approved in the EU, UK, or Canada.
45-second read · 4 questions answered below
What does this do?
The bill creates a fast-track FDA approval process for drugs treating life-threatening diseases that are already legally sold in the European Union, United Kingdom, or Canada. The FDA would have 30 days to decide, but could later withdraw approval if new safety evidence emerges or the foreign regulator withdraws its own approval. It also speeds up permission to start U.S. clinical trials using foreign authorization, with the same 30-day window.
Who does it affect?
This mainly affects patients with rare or life-threatening diseases seeking new treatments, and pharmaceutical and biotech companies developing those drugs. The FDA would also be affected, needing new review processes and a report to Congress after five years.
Why does it matter?
Relying on foreign regulatory decisions to speed up U.S. approvals raises questions about whether this affects the FDA's usual safety review standards.
AI-drafted summary. Check it against the official text before you act on it.
Read the official bill on Congress.govMake the call
Where does it stand?
- IntroducedMar 17, 2026
- House committeeYou are here · Mar 17, 2026
- House vote
- Senate
- The president's desk
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the president.
Latest action: — Referred to the House Committee on Energy and Commerce.